Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders.
The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.
The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders.
GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -0.15 Increased by +28.57% | -0.20 Increased by +25.00% |
| Feb 29, 24 | -0.21 Increased by +34.38% | -0.20 Decreased by -5.00% |
| Nov 9, 23 | -0.11 Decreased by -1.00 K% | -0.20 Increased by +45.00% |
| Aug 23, 23 | -0.15 Decreased by -1.60 K% | -0.25 Increased by +40.00% |
| May 11, 23 | -0.21 Decreased by -90.91% | -0.22 Increased by +4.55% |
| Mar 2, 23 | -0.32 Decreased by -255.56% | -0.17 Decreased by -88.24% |
| Nov 10, 22 | -0.01 Increased by +75.00% | -0.16 Increased by +93.75% |
| Aug 23, 22 | 0.01 Increased by +120.00% | -0.17 Increased by +105.88% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.65 M Decreased by -198.35% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.73 M Decreased by -204.19% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.11 M Decreased by -244.01% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -16.81 M Decreased by -310.93% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | 5.74 M Increased by +412.68% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | 7.42 M Increased by +449.08% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -3.52 M Decreased by -206.35% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -4.09 M Decreased by -1.16 K% | Decreased by N/A% Decreased by N/A% |